NCT03688152已完成1 期
A Phase 1b, Multicenter, Open-Label Study of the Safety and Tolerability of INCB053914 in Combination With INCB050465 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 9
- 试验地点
- 3
- 主要终点
- Number of treatment-emergent adverse events (TEAEs)
研究概览
简要总结
The purpose of this study is to evaluate the safety and tolerability of INCB053914 in combination with INCB050465 in relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Relapsed or refractory DLBCL, which has been histologically documented, defined as having received at least 2 but no more than 5 prior systemic treatment regimens (eg, an anti-CD20 antibody, an anti-CD20 antibody with or without chemotherapy, or chemotherapy alone) and ineligible for further treatment with standard of care.
- •Willing to undergo pretreatment and on-treatment incisional or excisional biopsy of nontarget adenopathy or extranodal lesions. Provision of the most recent, available archived tumor biopsy may satisfy the pretreatment biopsy.
- •Measurable disease as defined by the Lugano classification criteria:
- •≥ 1 measurable nodal lesion (≥ 1.5 cm in longest dimension) or ≥ 1 measurable extranodal lesion (> 1 cm in longest dimension) on CT scan or MRI
- •≥ 1 PET-avid lesion.
- •Eastern Cooperative Oncology Group performance status 0 to
- •Willingness to avoid pregnancy or fathering children based on protocol-defined the criteria.
排除标准
- •Laboratory values outside the protocol-defined range at screening unless approved by the medical monitor.
- •Primary mediastinal (thymic) large B-cell lymphoma or Richter's Syndrome.
- •Known brain or central nervous system metastases or history of uncontrolled seizures.
- •Radiotherapy with a wide field of radiation within 4 weeks or radiotherapy with a limited field of radiation for palliation within 2 weeks of the first dose of study treatment.
- •Allogeneic stem cell transplant within the last 6 months, or active graft-versus-host disease following allogeneic transplant, or autologous stem cell transplant within the last 3 months before the date of the first dose of study treatment.
- •Use of immunosuppressive therapy following allogenic transplant within 28 days of the first dose of study treatment.
- •Prior treatment with a PIM inhibitor, selective PI3Kδ inhibitor (eg, idelalisib), or a pan-PI3K inhibitor.
- •Receipt of anticancer medications, therapies, or investigational drugs within protocol-defined intervals before the date of the first dose of study treatment.
- •Current or previous other malignancy within 3 years of study entry, except cured (or treated with curative intent and no evidence of disease) basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix, or other noninvasive or indolent malignancy without sponsor approval.
- •History of liver function abnormality requiring investigation and/or treatment (eg, due to excessive alcohol or drug-induced liver injury).
- •Significant concurrent, uncontrolled medical condition including, but not limited to, renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, neurological, cerebral, or psychiatric disease.
- •Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment, and exposure to a live vaccine within 30 days of study treatment administration.
- •Known HIV infection.
- •Evidence of HBV or HCV infection.
- •History of stroke or intracranial hemorrhage within 6 months of the date of study treatment administration.
- •History of clinically significant or uncontrolled cardiac disease.
- •Presence of an abnormal ECG that is clinically meaningful. Screening QTc interval > 480 milliseconds is excluded (corrected by Fridericia).
- •Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study treatment and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.
研究组 & 干预措施
INCB053914 + INCB050465
Experimental
INCB053914 in combination with INCB050465.
干预措施: INCB053914 (Drug)
INCB053914 + INCB050465
Experimental
INCB053914 in combination with INCB050465.
干预措施: INCB050465 (Drug)
结局指标
主要结局
Number of treatment-emergent adverse events (TEAEs)
时间窗: Up to approximately 6 months
TEAE is defined as an adverse event reported for the first time or worsening of a pre-existing event after the first dose of study treatment.
次要结局
- Cmax of INCB053914 in combination with INCB050465(Day 15)
- Overall response rate(Up to approximately 6 months)
- Tmax of INCB053914 in combination with INCB050465(Day 15)
- AUC0-t of INCB053914 in combination with INCB050465(Day 15)
- Cl/F of INCB053914 in combination with INCB050465(Day 15)
- Duration of response(Up to approximately 6 months)
- Cmin of INCB053914 in combination with INCB050465(Day 15)
- Progression-free survival(Up to approximately 6 months)
研究者
研究点 (3)
Loading locations...
相似试验
终止
1 期
A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C MutationAdvanced Solid TumorsNCT06039384Incyte Corporation6
终止
1 期
A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid TumorsAdvanced Solid TumorsNCT05949632Incyte Corporation5
终止
1 期
Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast CancerBreast CancerNCT01254136Incyte Corporation20
终止
1 期
Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid TumorsHepatocellular Carcinoma (HCC)Renal Cell Carcinoma (RCC)Microsatellite Instability - High (MSI-H)Mismatch Repair Deficient (dMMR)Colorectal Carcinoma (CRC)MelanomaNCT05909995Incyte Corporation8
终止
2 期
INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin LymphomaRefractory Hodgkin LymphomaRecurrent Adult Hodgkin's LymphomaNCT02456675Incyte Corporation8